GlassScriptPhysician profile
Sandra D Yale
NPI 1619921194
$5,394.13
in general payments reported to CMS, 2019-2025
32 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $703 · 2021: $580 · 2022: $756 · 2023: $696 · 2024: $983 · 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,082.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,054.65 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $730.91 | 2020-2025 | |
| Pfizer INC. | $573.31 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.93 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $300.06 | 2022-2025 | Ozempic, Rybelsus |
| Insulet Corporation | $255.81 | 2024-2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $240.53 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $225.34 | 2019-2022 | |
| Abbvie INC. | $159.03 | 2021-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.79 | 2023-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $151.95 | 2022-2025 | |
| Edwards Lifesciences Corporation | $124.34 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Corcept Therapeutics | $123.33 | 2024-2025 | Korlym |
| Averitas Pharma INC. | $121.27 | 2024-2025 | Qutenza |
| Lilly USA, LLC | $112.36 | 2021-2025 | Jardiance, Emgality |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $94.41 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $85.46 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $74.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $56.69 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $48.06 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $43.14 | 2025 | |
| Paratek Pharmaceuticals, INC. | $34.05 | 2024-2025 | Nuzyra |
| Dexcom, INC. | $33.51 | 2025 | Dexcom G6 Transmitter |
| Janssen Scientific Affairs, LLC | $31.90 | 2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $25.05 | 2020 | |
| Bausch Health US, LLC | $21.97 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.89 | 2024 | |
| Esperion Therapeutics, INC. | $18.56 | 2021 | |
| Sobi, INC | $18.30 | 2019 | |
| Mylan Specialty L.P. | $17.73 | 2023 | Yupelri |
| Seqirus USA INC | $13.99 | 2025 | Flucelvax, Fluad |
| Teva Pharmaceuticals USA, INC. | $13.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Yale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.